Page 71 - Read Online

Chalatsa et al. Neuroimmunol Neuroinflammation 2020;7:132-40 I http://dx.doi.org/10.20517/2347-8659.2020.01 Page 139

39. Chen XQ, Niu JP, Peng RQ, Song YH, Xu N, et al. The early diagnosis of Parkinson’s disease through combined biomarkers. Acta Neurol
Scand 2019;140:268-73.
40. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, et al. Plasma alpha-synuclein in patients with Parkinson’s disease with and
without treatment. Mov Disord 2010;25:489-93.
41. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, et al. The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple
system atrophy. J Neural Transm 2006;113:1435-9.
42. Chang CW, Yang SY, Yang CC, Chang CW, Wu YR. Plasma and serum alpha-synuclein as a biomarker of diagnosis in patients with
Parkinson’s disease. Front Neurol 2019;10:1388.
43. Ng ASL, Tan YJ, Lu Z, Ng EYL, Ng SYE, et al. Plasma alpha-synuclein detected by single molecule array is increased in PD. Ann Clin
Transl Neurol 2019;6:615-9.
44. Lin CH, Liu HC, Yang SY, Yang KC, Wu CC, et al. Plasma pS129-alpha-synuclein is a surrogate biofluid marker of motor severity and
progression in Parkinson’s disease. J Clin Med 2019;8.
45. Lin CH, Yang SY, Horng HE, Yang CC, Chieh JJ, et al. Plasma biomarkers differentiate Parkinson’s disease from atypical parkinsonism
syndromes. Front Aging Neurosci 2018;10:123.
46. Lin CH, Yang SY, Horng HE, Yang CC, Chieh JJ, et al. Plasma alpha-synuclein predicts cognitive decline in Parkinson’s disease. J Neurol
Neurosurg Psychiatry 2017;88:818-24.
47. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in
Parkinson’s disease. Neurosci Lett 2010;480:78-82.
48. Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein
level. Arch Neurol 2010;67:1350-6.
49. Li QX, Mok SS, Laughton KM, McLean CA, Cappai R, et al. Plasma alpha-synuclein is decreased in subjects with Parkinson’s disease.
Exp Neurol 2007;204:583-8.
50. Cariulo C, Martufi P, Verani M, Azzollini L, Bruni G, et al. Phospho-S129 alpha-synuclein is present in human plasma but not in
cerebrospinal fluid as determined by an ultrasensitive immunoassay. Front Neurosci 2019;13:889.
51. Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, et al. A longitudinal study on alpha-synuclein in blood plasma as a biomarker
for Parkinson’s disease. Sci Rep 2013;3:2540.
52. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, et al. Red blood cells are the major source of alpha-synuclein in blood.
Neurodegener Dis 2008;5:55-9.
53. Tian C, Liu G, Gao L, Soltys D, Pan C, et al. Erythrocytic alpha-Synuclein as a potential biomarker for Parkinson’s disease. Transl
Neurodegener 2019;8:15.
54. Adler CH, Serrano GE, Zhang N, Hinni ML, Lott DG, et al. Feasibility of repeat and bilateral submandibular gland needle biopsies in
Parkinson’s disease. Parkinsonism Relat Disord 2019;68:69-72.
55. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy
body disease and sporadic Parkinson’s disease. Acta Neuropathol 2010;119:703-13
56. Kang W, Chen W, Yang Q, Zhang L, Zhang L, et al. Salivary total alpha-synuclein, oligomeric alpha-synuclein and SNCA variants in
Parkinson’s disease patients. Sci Rep 2016;6:28143.
57. Vivacqua G, Suppa A, Mancinelli R, Belvisi D, Fabbrini A, et al. Salivary alpha-synuclein in the diagnosis of Parkinson’s disease and
Progressive Supranuclear Palsy. Park Relat Disord 2019;63:143-8.
58. Al-Nimer MSM, Mshatat SF, Abdulla HI. Saliva alpha-synuclein and a high extinction coefficient protein: a novel approach in assessment
biomarkers of Parkinson’s disease. N Am J Med Sci 2014;6:633-7.
59. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson’s disease.
Brain 2011;134:178.
60. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005;25:6016-24.
61. Recasens A, Dehay B. Alpha-synuclein spreading in Parkinson’s disease. Front Neuroanat 2014;8:159.
62. Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, et al. Lysosomal dysfunction increases exosome-mediated alpha-
synuclein release and transmission. Neurobiol Dis 2011;42:360-7.
63. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, et al. Cell-produced alpha-synuclein is secreted in a calcium-
dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010;30:6838-51.
64. Von Bartheld CS, Altick AL. Multivesicular bodies in neurons: distribution, protein content, and trafficking functions. Prog Neurobiol
2011;93:313-40.
65. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers.
Mol Neurodegener 2012;7:42.
66. Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative
diseases. Front Physiol 2012;3:124.
67. Chang C, Lang H, Geng N, Wang J, Li N, et al. Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of
neurodegeneration in PD. Neurosci Lett 2013;548:190-5.
68. Zhao ZH, Chen ZT, Zhou RL, Zhang X, Ye QY, et al. Increased DJ-1 and α-synuclein in plasma neural-derived exosomes as potential
markers for Parkinson’s disease. Front Aging Neurosci 2018;10:438.
69. Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, et al. Induction of α-synuclein aggregate formation by CSF exosomes from
patients with Parkinson’s disease and dementia with Lewy bodies. Brain 2016;139:481-94.